Dr. Kim is head of oncology strategic combinations at AstraZeneca. Prior to joining AstraZeneca, he was director of the Division of Oncology Products in the Office of Hematology Oncology Products at the U.S. Food and Drug Administration, where he was tasked with evaluation and regulation of oncology drug products in development and approved for breast, genitourinary and gynecologic cancers. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products and therapy dose optimization strategies for cancer medicines.
Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.